This company has been acquired
Marrone Bio Innovations Balance Sheet Health
Financial Health criteria checks 2/6
Key information
139.3%
Debt to equity ratio
US$31.87m
Debt
| Interest coverage ratio | n/a |
| Cash | US$9.36m |
| Equity | US$22.87m |
| Total liabilities | US$53.34m |
| Total assets | US$76.21m |
Recent financial health updates
Is Marrone Bio Innovations (NASDAQ:MBII) Using Too Much Debt?
Mar 13
Does Marrone Bio Innovations (NASDAQ:MBII) Have A Healthy Balance Sheet?
Dec 09
Recent updates
Marrone Bio Innovations shareholders approve merger deal with Bioceres Crop Solutions
Jul 11Time To Worry? Analysts Are Downgrading Their Marrone Bio Innovations, Inc. (NASDAQ:MBII) Outlook
Aug 21Marrone Bio Innovations, Inc. (NASDAQ:MBII) Is Expected To Breakeven In The Near Future
Apr 08Is Marrone Bio Innovations (NASDAQ:MBII) Using Too Much Debt?
Mar 13What Kind Of Investors Own Most Of Marrone Bio Innovations, Inc. (NASDAQ:MBII)?
Feb 15Marrone Bio Innovations (NASDAQ:MBII) Shareholders Have Enjoyed A 75% Share Price Gain
Jan 25When Will Marrone Bio Innovations, Inc. (NASDAQ:MBII) Turn A Profit?
Jan 04Does Marrone Bio Innovations (NASDAQ:MBII) Have A Healthy Balance Sheet?
Dec 09Marrone Bio Innovations, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 10Financial Position Analysis
Short Term Liabilities: MBII's short term assets ($33.0M) do not cover its short term liabilities ($41.7M).
Long Term Liabilities: MBII's short term assets ($33.0M) exceed its long term liabilities ($11.6M).
Debt to Equity History and Analysis
Debt Level: MBII's net debt to equity ratio (98.4%) is considered high.
Reducing Debt: MBII had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MBII has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: MBII has less than a year of cash runway if free cash flow continues to grow at historical rates of 11.3% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/07/13 16:59 |
| End of Day Share Price | 2022/07/12 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Marrone Bio Innovations, Inc. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nathan Weinstein | Aegis Capital Corporation |
| Benjamin Kallo | Baird |
| Benjamin Klieve | B. Riley Wealth |